- Home
- SRRK vs FTDR Comparison
SRRK vs FTDR Comparison
Compare SRRK & FTDR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRRK
- FTDR
- Stock Information
- Founded
- SRRK 2012
- FTDR 1971
- Country
- SRRK United States
- FTDR United States
- Employees
- SRRK N/A
- FTDR N/A
- Industry
- SRRK Biotechnology: Biological Products (No Diagnostic Substances)
- FTDR Diversified Commercial Services
- Sector
- SRRK Health Care
- FTDR Finance
- Exchange
- SRRK Nasdaq
- FTDR Nasdaq
- Market Cap
- SRRK 4.2B
- FTDR 3.6B
- IPO Year
- SRRK 2018
- FTDR 2018
- Fundamental
- Price
- SRRK $37.70
- FTDR $57.10
- Analyst Decision
- SRRK Strong Buy
- FTDR Hold
- Analyst Count
- SRRK 7
- FTDR 6
- Target Price
- SRRK $40.43
- FTDR $48.60
- AVG Volume (30 Days)
- SRRK 793.4K
- FTDR 604.1K
- Earning Date
- SRRK 02-27-2025
- FTDR 02-27-2025
- Dividend Yield
- SRRK N/A
- FTDR N/A
- EPS Growth
- SRRK N/A
- FTDR 42.94
- EPS
- SRRK N/A
- FTDR 3.00
- Revenue
- SRRK N/A
- FTDR $1,827,000,000.00
- Revenue This Year
- SRRK N/A
- FTDR $4.78
- Revenue Next Year
- SRRK N/A
- FTDR $6.38
- P/E Ratio
- SRRK N/A
- FTDR $19.05
- Revenue Growth
- SRRK N/A
- FTDR 4.16
- 52 Week Low
- SRRK $6.76
- FTDR $29.41
- 52 Week High
- SRRK $46.98
- FTDR $63.49
- Technical
- Relative Strength Index (RSI)
- SRRK 41.93
- FTDR 43.77
- Support Level
- SRRK $35.35
- FTDR $56.43
- Resistance Level
- SRRK $38.61
- FTDR $60.19
- Average True Range (ATR)
- SRRK 1.80
- FTDR 1.54
- MACD
- SRRK -0.16
- FTDR -0.30
- Stochastic Oscillator
- SRRK 34.20
- FTDR 12.86
About SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGFβ1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.
About FTDR Frontdoor Inc.
Frontdoor Inc is a United States-based company that provides home service plans. It owns multiple home service brands including American Home Shield, HSA, OneGuard, and Landmark brands. Through its home service plans, the company helps its customers maintain their homes and protect against costly and unexpected breakdowns of essential home systems and appliances.